The objectives were two-fold: (1) determine whether the use of hydralazine as antihypertensive therapy during obesity development exacerbated obesity-related cardioacceleration and hormonal abnormalities; (2) determine whether the absence of hypertension in obesity attenuated obesity-related abnormalities in hemodynamics, cardiac hypertrophy, and hormonal profile. DESIGN: Female New Zealand White rabbits were divided into lean control (n ¼ 12), lean hydralazine-treated (n ¼ 9), obese control (n ¼ 11), and obese hydralazine-treated (n ¼ 8) groups. Pretreatment mean blood pressure (BP) and heart rate (HR) were determined using telemetry. Pretreatment BP was maintained during 12 weeks of obesity development using hydralazine. MEASUREMENTS: Chronically measured BP and HR; plasma/blood volume; wet and dry ventricular weights; body fat/water; and hormonal profile (plasma renin activity, aldosterone, cortisol, atrial natriuretic peptide, adrenaline, and noradrenaline). RESULTS: Hydralazine treatment in obese animals attenuated obesity-related renin-angiotensin system (RAS) activation. In contrast, RAS was activated in lean hydralazine, as indicated by increased plasma aldosterone. The absence of hypertension in obese hydralazine did not result in attenuation of cardioacceleration, cardiac hypertrophy, or intravascular volumes. CONCLUSIONS: Hydralazine treatment in obese rabbits did not exacerbate obesity-related cardiovascular and hormonal alterations. Cardioacceleration and cardiac hypertrophy persisted in obese hydralazine despite BP control, suggesting hypertension-independent effects of obesity on these variables. Hydralazine's effects on RAS activation differed in lean and obese rabbits, suggesting that the systemic effects of hydralazine as a control therapy in evaluation of antihypertensive medications may differ depending on the underlying pathology.
Introduction
Determining the independent influence of obesity on cardiac, cardiovascular, renal, and hormonal abnormalities is complicated by the concomitant occurrence of hypertension. Approaches to resolving this issue include statistical methods [1] [2] [3] or cross-sectional studies that recruit separate groups of obese-normotensive and obese-hypertensive subjects. 4 These approaches engender two related problems.
First, they assume that the negative sequelae of hypertension occur in a dichotomous manner and that the independent influence of obesity therefore is manifest when blood pressure (BP) is o140/80 mmHg. Secondly, they ignore potential interindividual differences in baseline BP. It has been hypothesized that obese individuals with BP o140/ 80 mmHg are actually 'hypertensive' relative to what their BP would be if they were lean. 5 This observation is supported by data which show a positive linear relationship between BP and body mass index even in the normotensive range, 6 and also by data demonstrating that obese-normotensive individuals almost always reduce BP when they lose weight. 7, 8 In contrast, it is possible to study hypertension-independent effects of obesity on cardiovascular function with an animal model of diet-induced obesity, 9 by utilizing a longitudinal analysis wherein a pre-obese BP is determined and subsequently maintained during obesity development. However, the choice of antihypertensive treatment is problematic. In evaluating various antihypertensive medications, animal studies most often use hydralazine as the control drug because of its pure vasodilatory action and lack of effect on other body systems. [10] [11] [12] [13] [14] [15] [16] In comparison, antihypertensive treatments such as angiotensin-converting enzyme inhibi-tors and angiotensin II receptor blockers have significant effects on cardiac and cardiovascular structure and/or function independent of their BP-lowering effects. 11, 17, 18 Despite its advantages, the antihypertensive efficacy of hydralazine is thought to be blunted by undesirable baroreceptor-mediated side effects such as reflex tachycardia, renin release, fluid retention, and activation of the sympathetic nervous system, a phenomenon known as pseudotolerance. 19 Yet, occurrence of this reflex response is seldom documented in animal models. In most cases, data on hormonal reflex responses are not reported, 10, [13] [14] [15] [16] [20] [21] [22] while the heart rate (HR) response has been reported as either increased 20 or unchanged. 21, 22, 15, 16 Use of hydralazine as antihypertensive therapy in an obesity-hypertension model is further complicated by the fact that potential side effects are similar to physiological changes often seen in obesity (e.g., tachycardia and activation of the reninangiotensin system (RAS)). 9, 23, 24 Therefore, the purposes of this study were two-fold. First, using the rabbit model, we sought to determine whether the use of hydralazine as an antihypertensive therapy would exacerbate cardiovascular and hormonal alterations already present in obesity. If cardiovascular and hormonal effects of hydralazine were neutral, we would be able to determine whether the absence of hypertension would attenuate obesity-related abnormalities in hemodynamics, cardiac hypertrophy, and hormonal profile.
Methods

Animals
Experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of North Texas Health Science Center. All animal care and use programs were carried out according to the Guide for the Care and Use of Laboratory Animals (NIH Publication 86-23, revised 1985) and the regulations of the Animal Welfare Act. Female New Zealand White rabbits were purchased when they were approximately 15-17 weeks old, weighing 3.25-3.75 kg (Myrtle's Rabbitry, Thompson Station, TN, USA). They were housed individually in a humidity-and temperature-controlled room with a 12-h light cycle, and fed 100-120 g per day of standard rabbit chow (Prolab s Breeder Rabbit chow, Purina Mills, St Louis, MO, USA). After a 1-week acclimation period, they were randomly divided into four groups: lean control (n ¼ 12), lean hydralazine-treated (n ¼ 9), obese control (n ¼ 11), and obese hydralazine-treated (n ¼ 8). Lean and obese controls served as benchmarks for normal and abnormal structure/function, respectively. In the obese hydralazine-treated group, obesity-related increases in BP were blocked in order to produce an obese-normotensive group. The lean groups ate a maintenance diet, 25 while obese groups were given a high fat diet, ad libitum, consisting of standard rabbit chow with 10% added fat. The excess fat in the diet was 2/3 corn oil and 1/3 lard. Experiments were performed after rabbits had been on their respective diets for 12 weeks.
Telemetry monitoring
In order to monitor daily HR and BP, telemetry transmitters (TA11PA-D70, Data Sciences International, Minneapolis, MN, USA) were aseptically implanted in the iliac artery under isoflurane anesthesia, prior to beginning the dietary protocol. Data were collected for a 4 s interval every 3 min. The daily averages of BP and HR were calculated from data collected between 1100 and 0700 h. From the daily averages, a weekly average was calculated. After 13-16 day postsurgical recovery, data were collected for 1 week to establish each animal's control value of BP.
Hydralazine treatment
Starting in week 2 of the dietary protocol, lean and obese hydralazine-treated groups received 6 and 10-14 mg/kg/day, respectively, of hydralazine (s.c.) dissolved in saline. The dosages were chosen to maintain the control value of mean BP.
Acute experiment Hormone analyses. After 12 weeks, fasting arterial blood samples were taken for measurement of plasma protein, hematocrit, plasma renin activity (PRA), aldosterone (ALDO), cortisol, atrial natriuretic peptide (ANP), adrenaline, and noradrenaline. Samples were placed in appropriate chilled blood collection tubes and centrifuged at 1200 g for 15 min at 41C. Plasma was stored at À901C until assay. Hematocrit was measured in duplicate using microhematocrit tubes. Plasma protein was measured in duplicate by refractometry. Plasma catecholamines were extracted with alumina, separated by HPLC, and quantified amperometrically in an electrochemical detector. Peptide and steroid hormones were determined in double-antibody and charcoal-based radioimmunoassay systems using both commercial and locally developed reagents. Where applicable, radioligands were iodinated with chloramine-T and purified by ion exchange/size exclusion chromatography.
Blood and plasma volume. Blood and plasma volumes were measured using the Evan's blue dye procedure. First, a control arterial blood sample (3 ml) was taken. This was followed by a venous injection of Evan's blue dye (5 mg/kg); 2 ml arterial blood samples were then taken after 10, 20, and 40 min. The optical density of plasma samples was determined and dye concentration at time zero was extrapolated from a plot of time vs plasma dye concentration. Dye concentration at time zero, total amount of dye injected, and hematocrit were used to determine plasma and blood volumes.
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Cardiac hypertrophy
After sacrifice, the heart was excised, atria cut away, and right and left ventricles weighed separately. Ventricles were subsequently freeze-dried to a constant weight and weighed again to the nearest 0.1 mg.
Body composition analysis
To determine fat and water composition, 2-3 g samples of whole body homogenate were assayed as described previously. 9 Triplicate samples from each animal were assayed and the average value used in all analyses.
Statistical analyses
To determine whether hydralazine treatment exacerbated obesity-related abnormalities, we used an unpaired t-test comparing obese control and obese hydralazine-treated groups. When the effects of hydralazine were neutral, this analysis was used to test whether the absence of hypertension during obesity development attenuated obesity-related abnormalities. Unpaired t-tests between lean control and lean hydralazine-treated groups were used to test for the independent effects of hydralazine. Our initial analysis indicated that there were differences in body weight between control and respective hydralazine-treated groups. Therefore, analyses were repeated using subsets of animals that did not differ significantly in body weight. Feed consumption data were analyzed using repeated-measures analysis of variance.
Results
Animal characteristics
Group characteristics are listed in Table 1 . Mean daily BP measured during week 12 was significantly lower in obese hydralazine-treated compared with obese controls (Pr0.05). However, obese controls had greater body weight as well as greater body fat percentage and fat weight compared with obese hydralazine-treated (Pr0.05). Lean controls had greater body fat percentage and fat weight compared with lean hydralazine-treated, despite significantly lower body weight (Pr0.05). Despite differences in body weight and body composition between control and hydralazine-treated groups, dry right and left ventricular weights did not differ significantly in either lean or obese animals (Table 1) . Similarly, intravascular volumes did not differ between control and hydralazinetreated animals. However, plasma protein concentration was significantly higher (Pr0.05, Table 1 ), while hematocrit tended to be higher (Pr0.10, Table 1 ) in obese controls compared with obese hydralazine-treated.
Lower body weight in obese hydralazine-treated after 12 weeks was associated with lower overall feed consumption (11.870.4 vs 13.570.4 kg, respectively, Pr0.05). Feed consumption during week 1 of the protocol was similar in obese controls and obese hydralazine-treated (17076 vs 16979 g, respectively), but dropped in obese hydralazine-treated beginning in week 2 when hydralazine treatment began (13775 vs 164710 g, respectively). This may be related to nausea, a potential side effect of hydralazine. 19 Hormone concentrations PRA did not differ significantly between lean groups, but ALDO was significantly higher in lean hydralazine-treated compared with lean controls (Pr0.05, Figure 1a , b). In contrast, hydralazine treatment in obese rabbits resulted in lower PRA (Pr0.10, Figure 1a ) and ALDO (Pr0.05, Figure 1b) concentrations. There were no significant differences between controls and hydralazine-treated animals in plasma concentrations of cortisol, ANP, noradrenaline, or adrenaline (Table 2) .
Animal characteristics (groups matched for body weight)
Since control and hydralazine-treated groups differed in body weight, it was possible that group differences in other variables were due to differing body weight and not to Blood pressure, hydralazine, and obesity JF Carroll et al hydralazine treatment. In order to test the effect of differing body weights, the heaviest animal from lean hydralazinetreated and the four heaviest animals from obese controls were eliminated from analyses so that control and respective hydralazine-treated groups no longer differed significantly in body weight. Results of these analyses are shown in Table 3 .
BP in obese hydralazine-treated was 10% lower than in obese controls, but this difference was not significant. We believe that this outcome was due to the reduced sample size since the percentage difference is similar to the significant differences that we have previously noted between lean and obese rabbits. 9, [26] [27] [28] Further, acutely measured BP was significantly lower in obese hydralazine-treated compared with obese controls (84.771.8 vs 90.271.5 mmHg, respectively, Pr0.05).
Despite equivalent body weight, body fat weight and percentage were still significantly higher in obese controls compared with obese hydralazine-treated (Pr0.05), while body water percentage was lower (50.471.4 vs 54.871.1%, respectively, Pr0.05). In lean rabbits, percent body fat and fat weight were lower in lean hydralazine-treated compared with lean controls (Pr0.05). Body water percentage tended to be higher in lean hydralazine-treated compared with lean controls (65.970.7 vs 63.071.2%, respectively, P ¼ 0.06). There were no significant differences between control and respective hydralazine-treated groups in the dry right and left ventricular weights or intravascular volumes (Table 3) . However, hematocrit and plasma protein concentrations were significantly higher in obese controls compared with obese hydralazine-treated (Pr0.05).
Hormone concentrations (groups matched for body weight)
Using control and hydralazine-treated groups that did not differ significantly in weight, we re-analyzed plasma hormones (Table 4) . In lean rabbits, hydralazine treatment elevated ALDO (Pr0.05, Table 4 ). In contrast, ALDO was 57% lower (Pr0.05) and ALDO/PRA 40% lower (P ¼ 0.06) in obese hydralazine-treated compared with obese controls. There were no significant differences between controls and respective hydralazine-treated animals in plasma concentrations of cortisol, ANP, noradrenaline, or adrenaline (data not shown).
Discussion
We demonstrated that the arterial vasodilator hydralazine is effective in controlling BP during development of obesity in the rabbit model, and that the pseudotolerance phenomenon associated with vasodilation-induced, baroreceptor- Blood pressure, hydralazine, and obesity JF Carroll et al mediated sympathetic activation 19 is either absent or differently expressed in lean and obese animals. In obese rabbits, hydralazine treatment controlled BP, attenuated activation of RAS, and did not exacerbate obesity-related cardioacceleration. In contrast, RAS was activated in hydralazine-treated lean rabbits, as evidenced by increased plasma ALDO. Finally, these data indicate that control of hypertension in obesity did not attenuate obesity-related effects on cardioacceleration, cardiac hypertrophy, and intravascular volumes. Hydralazine is commonly used in animal studies as the control treatment in the evaluation of other antihypertensive therapies. [10] [11] [12] [13] [14] [15] [16] However, because hydralazine induces direct relaxation of vascular smooth muscle in resistance vessels, it is thought to provoke baroreceptor-mediated sympathetic activation. As a result, the potential side effects include increased HR and cardiac output, and RAS activation. 19 In humans, these side effects are alleviated by combining hydralazine with b-blockers to blunt cardiac sequelae, and diuretics to control fluid retention and plasma volume expansion. In contrast, hydralazine is commonly used as monotherapy in animal studies, but its side effects are often not reported. As some of the potential side effects of hydralazine (eg, tachycardia, RAS activation, and plasma volume expansion) are already exhibited in obesity, 9, 23, 24 we documented whether the use of hydralazine as antihypertensive therapy exacerbated these effects.
Interestingly, hydralazine treatment resulted in different manifestations in lean and obese animals. In lean animals, RAS was activated, as evidenced by increased ALDO. However, PRA was not altered, demonstrating that measuring single components of RAS may give an incomplete picture of physiological function. In contrast, RAS activation was attenuated in obese hydralazine-treated, with PRA and ALDO lowered by 35 and 57%, respectively. In light of RAS activation seen in lean hydralazine-treated, this reduction may be particularly significant. The cause of RAS attenuation in obese hydralazine-treated is unknown, but may be related to improved renal blood flow as a result of arterial vasodilation. RAS attenuation is not likely due to inhibition by ANP 29, 30 since ANP was not increased in obese hydralazine-treated. These data suggest that effects of hydralazine as a control treatment may be altered by underlying pathology or phenotype. Further, despite RAS attenuation in obese hydralazine-treated, a comparison of obese hydralazinetreated and lean controls demonstrated that PRA tended to be higher (P ¼ 0.09) and ALDO/PRA lower (P ¼ 0.08) in obese hydralazine-treated, suggesting that obesity still exerted effects on RAS independent of hypertension. Cardiac hypertrophy in obesity may be related to preloadand afterload-induced ventricular remodeling, 31 prolonged neurohumoral activation of RAS, [32] [33] [34] and/or alterations in other hormones such as ANP 35 or insulin. 31 Despite reduced BP and attenuated activation of RAS in obese hydralazinetreated, cardiac hypertrophy persisted, suggesting that preload played a more important role in ventricular hypertrophy in this model than hypertension-induced afterload or RAS. Further, our data are in agreement with findings that hydralazine does not have an independent effect on cardiac hypertrophy. [12] [13] [14] 16, 36 Hydralazine-treated groups did not have significantly different wet or dry ventricular weights compared with their respective controls. While we did not measure chamber volumes, the neutral effect of hydralazine on intravascular volumes suggested that preload-initiated obesity-related cardiac chamber remodeling 37 would be unaltered by hydralazine. The lack of difference in wet 38 While our data would suggest a hypertensionindependent effect of obesity on cardiac hypertrophy, further analyses are necessary to determine whether BP control in obesity induced alterations in cardiac composition. While there were no differences between control and hydralazine-treated animals in intravascular volumes, body water was greater and body fat lower in hydralazine-treated animals. This may be related to the purported hydralazinerelated side effect of edema. 19 Since lean groups were maintained at equivalent body weights, the gradual increase in body water occurred at the expense of body fat. Obese animals were fed ad lib so that the increasing body water along with the increasing body weight obscured the attenuation in body fat accretion. These data demonstrate the importance of body composition analysis in addition to body weight measurement in assessing the effects of obesityrelated interventions. However, the mechanism responsible for increased body water in lean and obese hydralazinetreated groups is unclear, since both ALDO and ALDO/PRA changed in opposite directions in these groups. Further studies of renal function and sympathetic nervous system influences on the kidney are needed to clarify these questions. We did not find that hydralazine treatment altered sympathetic activation in either lean or obese animals, as indicated by unchanged plasma adrenaline and noradrenaline. While it is unlikely that a single measurement of plasma catecholamines adequately reflects the chronic state of the sympathetic nervous system, a lack of sympathetic activation was also suggested by unaltered HR responses in hydralazine-treated animals compared with respective controls. Nevertheless, we cannot rule out sympathetically mediated effects in individual organs/tissues.
An emerging area of study in obesity is that of adipose tissue as an endocrine organ. All components of RAS are evident in adipocytes, but their contribution to hypertension and metabolic disease is still uncertain. 39, 40 Further, different levels of expression of RAS components are evident in subcutaneous vs visceral adipose tissue. 41 Other peptide hormones secreted by adipose tissue include leptin, adipsin, plasminogen activator inhibitor-1 (PAI-1), adiponectin, and resistin, and their regulation is altered when fat mass is markedly altered. 42 Therefore, we cannot exclude the possibility that reduced fat mass in obese hydralazine-treated contributed to altered plasma RAS components or to reduced BP. However, because we did not see similar directional changes in lean hydralazine-treated, we hypothesize that reduced adipocyte hormone secretion was not responsible for attenuated RAS in obese hydralazine-treated. From these data, we conclude that hydralazine treatment did not exacerbate cardiovascular and hormonal alterations in obesity, and in fact resulted in an unexpected reduction in baroreceptor-mediated RAS activation. Further, cardioacceleration and cardiac hypertrophy persisted in obese hydralazine-treated despite BP control, suggesting hypertensionindependent effects of obesity on these variables. It is evident that documentation of systemic effects of hydralazine as a control therapy in evaluation of antihypertensive medications is often lacking, but may provide crucial information regarding integrated physiological function, which may differ depending on the underlying pathology. Finally, further studies are clearly warranted to determine the differential effects of hydralazine in lean and obese animals on cardiac composition, renal function, sympathetic nervous system/renal function relationships, and adipocyte biology.
